

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
Tohru Ohama, Ryota Kawase, Yasushi Sakata, Shin Izuya Yamashita	Chapter 21 Methods for studying the function of progranulin in atherosclerosis using both knockout mice models and in vitro studies	Andrew Bateman, Hugh P.J. Bennett, Siu Tim Cheung	Methods in Molecular Biology 1806 Springer Protocols: Progranulin Methods and Protocols	Humana Press	USA	2018	315-328
Shizuya Yamashita, Yuji Matsuzawa	Low HDL and high HDL syndromes	Luciano Martini	Encyclopedia of Endocrine Diseases, Second Edition	Elsevier	USA	2018	327-339
川尻剛照、山岸正和	脂質異常症の治療薬	小室一成、中村正人	循環器内科専門医バイブルシリーズ「虚血性心疾患」虚血性心疾患の二次予防	中山書店	東京	2018	300-305
川尻剛照、山岸正和	安定狭心症	伊藤浩、山下武志	循環器疾患最新の治療2018-2019	南江堂	東京	2018	83-86
三井田孝	TGの測定法と標準化	倉林正彦	高TG血症	最新医学社	大阪	2018	94-100
三井田孝	鑑別診断手順	日本動脈硬化学会	脂質異常症診療ガイド	日本動脈硬化学会	東京	2018	26-28
三井田孝	LDL-C測定法に計算式と直接法がありますがどう使い分ければよいですか？違いと使い方を教えてください	日本動脈硬化学会	脂質異常症診療ガイド	日本動脈硬化学会	東京	2018	142
三井田孝	LDL-C直接法は不正確だと聞きましたが本当ですか？	日本動脈硬化学会	脂質異常症診療ガイド	日本動脈硬化学会	東京	2018	142
三井田孝	中性脂肪	日本衛生検査所協会	50人の専門医が教える検査と検査値の話	日本衛生検査所協会	東京	2018	86-87

三井田孝	食事時間と検査値	日本衛生検査所協会	50人の専門医が教える検査と検査値の話	日本衛生検査所協会	東京	2018	128-129
小倉正恒、和田郁人、ス波真理子	原発性高TG血症治療の現状と新薬開発状況	倉林正彦	高TG血症	最新医学社	大阪	2018	184-191
佐々木誠、池脇克則	高TG血症とHDL代謝	倉林正彦	高TG血症	最新医学社	東京	2018	60-6

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Hori M, Miyauchi E, Son C, Harada-Shiba M	Detection of the benign c.2579C>T (p.A860V) variant of the LDLR gene in a pedigree-based genetic analysis of familial hypercholesterolemia.	J Clin Lipidol		in press	2019
Harada-Shiba M	How much further do we need to decrease LDL cholesterol levels in heterozygous familial hypercholesterolemia?	Atherosclerosis		in press	2019
Shirahama R, Ono T, Nagamatsu S, Sueta D, Takashio S, Chitosane T, Fujisue K, Sakamoto K, Yamamoto E, Izumiya Y, Kaikita K, Hokimoto S, Horii M, Harada-Shiba M, Kajiwara I, Ogawa H, Tsujita K	Coronary Artery Plaque Regression by a PCSK9 Antibody and Rosuvastatin in Double-heterozygous Familial Hypercholesterolemia with an LDL Receptor Mutation and a PCSK9 V4I Mutation	Intern Med	57	3551-3557	2018
Nose D, Horii M, Miyamoto Y, Imazumi S, Harada-Shiba M, Sakuma K, Miura S	Discontinuation of LDL apolipoprotein B synthesis with evolocumab in an FH patient with a duplication of exon 2-6 in the LDLR gene	Journal of Cardiology		in press	2019
Nohara A, Otsubo Y, Yanagi K, Yoshida M, Ikewaki K, Harada-Shiba M, Jurecka A	Safety and Efficacy of Lovastatin in Japanese Patients with Homozygous Familial Hypercholesterolemia (HoFH): Results from the AEGR-733-301 Long-Term Extension Study	J Atheroscler Thromb		in press	2019

Vallejo-Vaz AJ, Harada-Shiba M, Yamashita S, Catapano AL, Ray KK et al; On behalf of the EAS Familial Hypercholesterolemia Studies Collaboration (FHSC) Investigators	Overview of the current status of familial hypercholesterolemia care in over 60 countries - The EAS Familial Hypercholesterolemia Studies Collaboration (FHSC)	Atherosclerosis	277	234-255	2018
Harada-Shiba M, Ako J, Arai H, Hirayama A, Murakami Y, Nohara A, Ozaki A, Uno K, Nakamura M	Prevalence of familial hypercholesterolemia in patients with acute coronary syndrome in Japan: results of the EXPLORE-J study	Atherosclerosis	277	362-368	2018
Kakuta T, Fujita T, Fukushima S, Kawamoto N, Matsumoto Y, Yamashita K, Shimahara Y, Ishibashi-Ueda H, Harada-Shiba M, Kobayashi J	Two Cases of Surgical Management of Supravalvular Aortic Stenosis in Familial Hypercholesterolemia	Ann Thorac Surg	105(4)	e171-e174	2018
Harada-Shiba M, Arai H, Ishigaki Y, Ishibashi S, Okamura T, Ogura M, Dobashi K, Nohara A, Bujo H, Miyaudhi K, Yamashita S, Yokote K, Working Group by Japan Atherosclerosis Society for Making Guidance of Familial Hypercholesterolemia	Guidelines for Diagnosis and Treatment of Familial Hypercholesterolemia. 2017	J Atheroscler Thromb	25	751-770	2018

Kameyama N, Maruyama C, Kitagawa F, Nishii K, Uenomachi K, Kinatayama Y, Kogahara H, Chikamoto N, Kuwata Y, Torigoe J, Arimoto M, Tokumaru T, Ikekawa K, Nohara A, Otsubo Y, Yanagi K, Yoshida M, Harada-Shiba M	Dietary intake during 56 weeks of a low-fat diet for or lomitapide treatment in Japanese patients with homozygous familial hypercholesterolemia	J Atheroscler Thromb	26	72-83	2019
Harada-Shiba M, Ohta T, Ohtake A, Ogura M, Dobashi K, Nohara A, Yamashita S, Yokote K Joint Working Group by Japan Pediatric Society and Japan Atherosclerosis Society for Making Guidance of Pediatric Familial Hypercholesterolemia	Guidance for Pediatric Familial Hypercholesterolemia 2017	J Atheroscler Thromb	25	539-553	2018
Harada-Shiba M, Kastelein JP, Hovingh GK, Kaulik R, Ohtake A, Arisaka O, Ohta T, Okada T, Suganami H, Willerson A	Efficacy and safety of pitavastatin in children and adolescents with familial hypercholesterolemia in Japan and Europe	J Atheroscler Thromb	25	422-429	2018
Cesare R Sirtori, Shizuya Yamashita, Maria Francesca Greco, Alberto Corsini, Gerald Watts, Massimiliano Ruscica	Recent advances in synthetic pharmacotherapies for dyslipidemias.	European Journal of Preventive Cardiology		in press	
Yamashita S, Matsuda D, Matsuzawa Y	Clinical applications of a novel selective PPAR modulator, pemafibrate, in dyslipidemia and metabolic diseases.	J Atheroscler Thromb		in press	

Sairyo M, Kobayashi T, Masuda D, Kanno K, Zhu Y, Okada T, Koteseki M, Ohama T, Nishida M, Sakata Y, Yamashita S	A novel selective PPAR modulator (SPPARM-77 (pemafibrate), attenuates postprandial hypertriglyceridemia in mice	J Atherosclerosis Thromb	25	142-152	2018
Okada T, Ohama T, Okazaki M, Kanno K, Matsuda H, Sairyo M, Zhu Y, Saga A, Kobayashi T, Masuda D, Koseki M, Nishida M, Sakata Y, Yamashita S	Particle number analysis of lipoprotein subclasses by gel permeation HPLC in patients with cholesterol ester transfer protein deficiency.	PLoS One	13	e0190875	2018
Teramoto T, Kai T, Ozaki A, Crawford B, Arai H, Yamashita S	Treatment patterns and lipid profile in patients with familial hypercholesterolemia in Japan.	J Atherosclerosis Thromb	25	580-592	2018
Yamashita S, Masuda D, Arai H, Matsuzawa Y	Cultural barriers in the treatment of dyslipidemia: a survey of Japanese physician attitudes.	J Atherosclerosis Thromb	26	154-169	2019
Sturm CA, KnowlesWJ, Gidding S, Ahmad SZ, Ahmed DC, Ballantyne MC, Baum J, Bourbon M, Cuchel M, Hovingh K, Kastelein PJ, Lane RS, Nordestgaard GB, Santos RD, Harada-Shiba M, Sijbrands E, Yamashita S, Wilmore KA, Rader DJ	Convened by the Familial Hypercholesterolemia Foundation: Clinical genetic testing for familial hypercholesterolemia: JACC Scientific Expert Panel.	J Am Coll Cardiol	72	662-680	2018

<p>EAS Familial Hypercholesterolaemia Studies Collaboration; Vallejo-Vaza AJ, Harada-Shiba M, Yamashita S, et al; On behalf of the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) investigators</p>	<p>Overview of the current status of and initiatives related familial hypercholesterolaemia in over 60 countries participating in the EAS familial hypercholesterolaemia studies collaboration (FHSC).</p>	<p>Atherosclerosis</p>	<p>277</p>	<p>234-255</p>	<p>2018</p>
<p>Committee for Epidemiology and Clinical Management of Atherosclerosis; Kinoshita M, Yokote K, Arai H, Iida M, Ishigaki Y, Ishibashi S, Umemoto S, Egusa G, Ohmura H, Okamura T, Kihara S, Koba S, Saito I, Shoji T, Daida H, Tsukamoto K, Deguchi J, Dohi S, Dobashi K, Hamaguchi H, Hara M, Hiro T, Hiro S, Fujioka Y, Maruyama C, Miyamoto Y, Murakami Y, Yokode M, Yoshida H, Rakugi H, Wakatsuki A, Yamashita S</p>	<p>Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017.</p>	<p>J Atheroscler Thromb</p>	<p>25</p>	<p>846-984</p>	<p>2018</p>
<p>Pang J, Chan DC, Hu M, Muir A, Kwok S, Chang M-J, Florkowski CM, George P, Lin J, Marais AD, Nawawi HM, Gonzalez-Santos LE, Su T-C, Truong TH, Santos RD, Soran H, Tomlinson B, Yamashita S, Ademi Z, Watts GF</p>	<p>Comparative aspects of the care of familial hypercholesterolaemia in the "Ten Countries Study.</p>	<p>J Clin Lipidol.</p>		<p>in press</p>	

Nishino T, Horie T, Baba O, Sohma N, Hanada R, Kuwabara Y, Nakao T, Nishigaki M, Nishi H, Nakashima Y, Nakazeki F, Ide Y, Koyama S, Kimura M, Nagata M, Yoshida K, Takagi Y, Nakamura T, Hasegawa K, Miyamoto S, Kimura T, and *Ono K	SREBF1/MicroRNA-33b axis exhibits potent effect on unstable atherosclerotic plaque formation in vivo.	Arterioscler Thromb Vasc Biol.	38	2460-2473	2018
Baba O, Horie T, Nakao T, Hakuono D, Nakashima Y, Nishi H, Kuwabara Y, Nishigaki M, Nishino T, Ide Y, Nakazeki F, Koyama S, Kimura M, Hanada R, Kawahara M, Kimura T, and *Ono K	MicroRNA-33 regulates the population of peripheral inflammatory Ly6Chigh monocytes through dual pathways	Mol Cell Biol	38	e00604-17	2018
Ono K, Kuwabara Y, Horie T, Kimura T.	Long Non-Coding RNAs as Key Regulators of Cardiovascular Diseases	Circulation J.	82	1231-1236	2018
Tada H, Inaba S, Pozharitckai D, Kawashiri MA.	Prominent Tendon Xanthomas and Abdominal Aortic Aneurysm Associated with Cerebrotendinous Xanthomatosis Identified Using Whole Exome Sequencing.	Intern Med.	57	1119-1122	2018
Nakahashi T, Tada H, Sakata K, Yakuta Y, Tanaka Y, Nomura A, Gamou T, Terai H, Horita Y, Ikeda M, Namura M, Takamura M, Hayashi K, Yamagishi M, Kawashiri MA.	Paradoxical impact of decreased low-density lipoprotein cholesterol level at baseline on the long-term prognosis in patients with acute coronary syndrome.	Heart Vessel	33	695-705	2018
Tada H, Kawashiri MA, Nohara A, Inazu A, Mabuuchi H, Yamagishi M.	Assessment of arterial stiffness in patients with familial hypercholesterolemia.	J Clin Lipidol.	12	397-402	2018

Okada H, Tada H, Hayashi K, Kawashima H, Takata T, Sakata K, Nohara A, Mabuchi H, Yamagishi M, Kawashiri MA.	Aortic Root Calcification Score as an Independent Factor for Predicting Major Adverse Cardiac Events in Familial Hypercholesterolemia.	J Atheroscler Thromb.	25	634-642	2018
Nomura A, Tada H, Nohara A, Kawashiri MA, Yamagishi M.	Oral Fat Tolerance Test for Sitosterolemia and Familial Hypercholesterolemia: A Study Protocol.	J Atheroscler Thromb.	25	741-746	2018
Nakahashi T, Tada H, Sakata K, Nomura A, Ohira M, Mori M, Takamura M, Hayashi K, Yamagishi M, Kawashiri MA.	Additive Prognostic Value of Carotid Plaque Score to Enhance the Age, Creatinine, and Ejection Fraction Score in Patients with Acute Coronary Syndrome.	J Atheroscler Thromb.	25	709-719	2018
Tada H, Kawashiri MA, Nohara A, Sakata K, Inazu A, Mabuchi H, Yamagishi M, Hayashi K.	Remnant-like particles and coronary artery disease in familial hypercholesterolemia.	Clin Chim Acta.	482	120-123	2018
Kawashiri MA, Tada H, Nomura A, Yamagishi M.	Mendelian randomization: Its impact on cardiovascular disease.	J Cardiol.	72	307-313	2018
Tada H, Nomura A, Nohara A, Inazu A, Mabuchi H, Yamagishi M, Kawashiri MA.	Post-prandial Remnant Lipoprotein Metabolism in Sitosterolemia.	J Atheroscler Thromb.	25	1188-1195	2018
Tada H, Nomura A, Yamagishi M, Kawashiri MA.	First case of sitosterolemia caused by double heterozygous mutations in ABCG5 and ABCG8 genes.	J Clin Lipidol.	12	1164-1168	2018
Tada H, Nohara A, Inazu A, Sakuma N, Mabuchi H, Kawashiri MA.	Sitosterolemia, Hypercholesterolemia, and Coronary Artery Disease.	J Atheroscler Thromb.	25	783-789	2018
Tada H, Kawashiri MA, Nomura A, Yoshimura K, Itoh H, Komuro I, Yamagishi M.	Serum triglycerides predict first cardiovascular events in diabetic patients with hypercholesterolemia and retinopathy.	Eur J Prev Cardiol.	25	1852-1860	2018

Tada H, Kawashiri MA, Nomura A, Teramoto R, Hosomichi K, Nohara A, Inazu A, Mabuchi H, Tajima A, Yamagishi M.	Oligogenic familial hypercholesterolemia, LDL cholesterol, and coronary artery disease.	J Clin Lipidol.	12	1436-1444	2018
Tada H, Nohara A, Kawashiri MA.	Serum Triglycerides and Atherosclerotic Cardiovascular Disease: Insights from Clinical and Genetic Studies.	Nutrients.	10		2018
Nomura A, Tada H, Okada H, Nohara A, Ishikawa H, Yoshimura K, Kawashiri MA.	Impact of genetic testing on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia (GenTLe-FH): a randomised waiting list controlled open-label study protocol.	BMJ Open.	8	E023636	2018
Tada H, Kawashiri MA.	Genetic Variations, Triglycerides, and Atherosclerotic Disease.	J Atheroscler Thromb.	26	128-131	2019
Tada H, Nomura A, Okada H, Nakahashi T, Nozue T, Hayashi K, Nohara A, Yagi K, Inazu A, Michishita I, Mabuchi H, Yamagishi M, Kawashiri MA.	Clinical whole exome sequencing in severe hypertriglyceridemia.	Clin Chim Acta	488	31-39	2019
Tada H, Nohara A, Inazu A, Mabuchi H, Kawashiri MA.	Remnant lipoproteins and atherosclerotic cardiovascular disease.	Clin Chim Acta	490	1-5	2019

Okada H, Nakaniishi C, Yoshida S, Shimojima M, Yokawa J, Mori M, Tada H, Yoshimuta T, Hayashi K, Yamano T, Hanayama R, Yamagishi M, Kawashiri MA.	Function and Immunogenicity of Gene-corrected iPSC-derived Hepatocyte-Like Cells in Restoring Low Density Lipoprotein Uptake in Homozygous Familial Hypercholesterolemia.	Sci Rep.	9	4965	2019
Nagahara K, Hachiya R, Tada H, Okada H, Yamagishi M, Dobashi K, Mizuno K, Hasegawa Y.	A Japanese case of familial hypercholesterolemia with a novel mutation in the LDLR gene.	Clin Ped Endocrinol	29	19-22	2018
Takanashi M, Kimura T, Li C, Tanaka M, Matsuhashi A, Yoshida H, Noda A, Xu P, Takase S, Okazaki S, Iizuka Y, Kumagai H, Ikeda Y, Gotoda T, Takahashi M, Yagyu H, Ishibashi S, Yamauchi T, Kadowaki T, Liang G, Okazaki H	Critical Role of SREBP-1c Large-VLDL Pathway in Environment-Induced Hypertriglyceridemia of Apo AV D deficiency.	Arterioscler Thromb Vasc Biol	39(3)	373-386	2019
Eguchi J, Miyashita K, Fukumachi I, Nakajima K, Murakami M, Kawahara Y, Yamashita T, Ohta Y, Abe K, Nakatsuka A, Mino M, Takase S, Okazaki H, Hegele RA, Ploug M, Hu X, Wada J, Young SG, Beigneux AP	GPIHBP1 autoantibody syndrome during interferon- α treatment.	J Clin Lipidol.	13(1)	62-69	2019

Nohara A, Ohmura H, Okazaki H, Ogura M, Kitagawa K, Koseki M, Sato K, Tsukamoto K, Yamashita S; Japan Atherosclerosis Society Working Group on Statement for Appropriate Use of PCSK9 Inhibitors	Statement for Appropriate Clinical Use of PCSK9 Inhibitors.	J Atheroscler Thromb	25(8)	747-750	2018
Nagasaka H, Hirano K, Yorifuji T, Komatsu H, Takatani T, Morioka I, Hirayama S, Miida T.	Treatment with medium chain fatty acids milk of CD36-deficient preschool children.	Nutrition	50	45-48	2018
Isshiki M, Hirayama S, Ueno T, Ito M, Furuta A, Yano K, Yamatani K, Sugihara M, Idei M, Miida T.	Apolipoproteins C-II and C-III as nutritional markers unaffected by inflammation.	Clin Chim Acta	481	225-230	2018
Hirayama S, Nagasaka H, Honda A, Komatsu H, Kodama T, Inui A, Morioka I, Kaji S, Ueno T, Ihara K, Yagi M, Kizaki Z, Bessho K, Kondou H, Yorifuji T, Tsukahara H, Iizima K, Miida T.	Cholesterol metabolism is enhanced in the liver and brain of children with citrin deficiency.	J Clin Endocrinol Metab	103(7)	2488-2497	2018
Yamashita Y, Nakada S, Yoshihara T, Nara T, Furuya N, Miida T, Hattori N, Arikawa-Hirasawa E.	Perlecan, a heparan sulfate proteoglycan, regulates systemic metabolism with dynamic changes in adipose tissue and skeletal muscle.	Sci Rep	8(1)	7766	2018

Ishibashi R, Takemoto M, Tsurutani Y, Kuroda M, Ogawa M, Wakabayashi H, Uesugi N, Nagata M, Imai N, Hattori A, Sakamoto K, Kitamoto T, Maezawa Y, Narita I, Hiroi S, Furuta A, Miida T, Yokote K.	Immune-mediated acquired lecithin-cholesterol acyltransferase deficiency: A case report and literature review.	J Clin Lipidol	12(4)	888-897	2018
Yano K, Hirayama S, Misawa N, Furuta A, Ueno T, Motoi Y, Seino U, Ebinuma H, Ikeuchi T, Schneider WJ, Bujo H, Miida T	Soluble LR11 competes with amyloid in binding to cerebrospinal- fluid-high-density lipoprotein.	Clin Chim Acta	489	29-34	2019
Sekijima Y, Koyama S, Yoshinaga Y, Koinuma M, Inaba Y.	Nationwide survey on cerebrotendinous xanthomatosis in Japan	J Hum Genet	63	271-280	2018

Sharma R, Matsuzaka T, Kaushik MK, Sugawara T, Ohno H, Wang Y, Motomura K, Shimura T, Okajima Y, Mizunoe Y, Ma Y, Saber ZM, Iwasaki H, Yatch S, Suzuki H, Aita Y, Han SI, Takeuchi Y, Yahagi N, Miyamoto T, Sekiya M, Nakagawa Y, Shimano H.	Octacosanol and policosanols prevent high-fat	Sci Rep.	26;9(1)	5169.	2019 Mar
Shichino S, Uehara S, Hashimoto S, Otsuji M, Abe J, Tsukui T, Deshimaru S, Nakajima T, Kosugi-Kanaya M, Shand FH, Inagaki Y, Shimano H, Matsushima K.	Transcriptome network analysis identifies protective role of the LXR/SREBP-1c axis in murine pulmonary fibrosis.	JCI Insight.	10;4(1).	[Epub ahead of print]	2019 Jan
Kodama S, Horikawa C, Fujihara K, Ishii D, Hattori M, Takeda Y, Kitazawa M, Matsubayashi Y, Shimano H, Kato K, Tanaka S, Sone H.	Relationship between intake of fruit separately from vegetables and triglycerides - A meta-analysis.	Clin Nutr ESPEN.	27	:53-58.	2018 Oct;
Araki M, Nakagawa Y, Oishi A, Han SI, Wang Y, Kumagai K, Ohno H, Mizunoe Y, Iwasaki H, Sekiya M, Matsuzaka T, Shimano H.	The Peroxisome Proliferator-Activated Receptor (PPAR α) Agonist Pemafibrate Protects against Diet-Induced Obesity in Mice.	Int J Mol Sci.	19(7).	pii: E2148. [Epub ahead of print]	2018 Jul 23;

Furukawa S, Suzuki H, Fujihara K, Kobayashi K, Iwasaki H, Sugano Y, Yatoh S, Sekiya M, Yahagi N, Shimano H.	Malondialdehyde-modified LDL-related variables are associated with diabetic kidney disease in type 2 diabetes.	Diabetes Res Clin Pract.	141	:237-243.	2018 Jul:
Yamamoto Y, Takei K, Arulmozhiaraja S, Sladek V, Matsuo N, Han SI, Matsuzaka T, Sekiya M, Tomokiwa T, Shoji M, Shigeta Y, Nakagawa Y, Tokiwa H, Shimano H.	Molecular association model of PPAR and its new specific and efficient ligand, pemafibrate: Structural basis for SPPARM.	Biochem Biophys Commun.	499(2):	239-245	2018 May;
Karasawa T, Kawashima A, Usui-Kawanishi F, Watanabe S, Kimura H, Kamata R, Shirasuna K, Kobayama Y, Sato-Tomita A, Matsuda	Saturated Fatty Acids Undergo Intracellular Crystallization and Activate the NLRP3 Inflammasome in Macrophages.	Arterioscler Thromb Vasc Biol.	38(4):	744-756.	2018 Apr;
Cho KI, Sakuma I, Sohn IS, Hayashi T, Shimada K, Koh KK	Best Treatment Strategies with Statins to Maximize Cardiometabolic Benefits	CIRCULATION JOURNAL	82	937-943	2019
Umegaki H, Makino T, Hayashi T, Cheng XW, Kuzuya M.	Cognitive Dysfunction in Urban-Community Dwelling Prefrail Older Subjects	JOURNAL OF NUTRITION HEALTH & AGING	22	549-555	2019
Nakayama N, Hayashi T, Miyachi M, Negi K, Watanabe K, Hirai M	Napping Improves HRV in Older Patients with Cardiovascular Risk Factors.	Western journal of nursing research	1949	9180925	2019

Komatsu T, Sakurai T, Wolska A, Amar MJ, Sakurai A, Vaisman BL, Sviridov D, Demosky S, Pryor M, Ikewaki K, Remaley AT	Apolipoprotein C-II Mimetic Peptide Promotes the Plasma Clearance of Triglyceride-Rich Lipid Emulsion and the Incorporation of Fatty Acids into Peripheral Tissues of Mice	J Nutr Metab	In press			2019
Kameyama N, Maruyama C, Kitagawa F, Nishii K, Uenomachi K, Kitayama Y, Koga H, Chikamoto N, Kuwata Y, Torigoe J, Arimoto M, Tokumaru T, Ikewaki K, Nohara A, Otsubo Y, Yanagi K, Yoshida M, Harada-Shiba M	Dietary Intake during 56 Weeks of a Low-Fat Diet for Lomitapide Treatment in Japanese Patients with Homozygous Familial Hypercholesterolemia.	J Atheroscler Thromb.	26	72-83		2019
Ito M, Ikewaki K.	Postprandial Hyperlipemia is an Indication for Additional Risk in Sitosterolemia	J Atheroscler Thromb	25	1183-4		2018
Nohara A, Otsubo Y, Yanagi K, Yoshida M, Ikewaki K, Harada-Shiba M, Jurecka A	Safety and Efficacy of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia (HoFH): Results from the AEGR-733-301 Long-Term Extension Study	J Atheroscler Thromb	26	368-77		2019
Takiguchi S, Aoyori M, Yakushiji E, Nakaya K, Sasaki M, Iizuka M, Uto-Kondo H, Terao Y, Yogo M, Komatsu T, Ogura M, Ikewaki K	Hepatic Overexpression of Endothelial Lipase Induces a Markedly Low HDL-Cholesterol but Maintains Macrophage Reverse Cholesterol Transport in Mice: Role of SR-BI/ABCA1-dependent pathways	Arterioscler Thromb Vasc Biol.	38	1454-67		2018
Sakuma I, Ikewaki K	Should Measures of High-Density Lipoprotein Function Be Added to the Low-Density Lipoprotein Cholesterol Target Level-Based Guidelines for Prevention of Atherosclerotic Disease?	Circ J	82	1251-2		2018

Mune M, Uto-Kondo H, Iteya I, Fujii Y, Ikeda S, Ikewaki K.	Vitamin E supplementation improves high-density lipoprotein and endothelial functions in end-stage kidney disease patients undergoing hemodialysis	Clin Nephrol	90	212-21	2018
Watanabe T, Nema T, Hiruta N, Murano T, Schneider WJ, Bujko H.	Lp8 is potentially associated with partial lecithin:cholesterol acyltransferase deficiency in a patient with primary biliary cirrhosis.	J Clin Lipidol.	12(5)	1157-1163	2018
Muratsu J, Kosaki M, Masuda D, Yasuga Y, Tomoyama S, Ataka K, Yagi Y, Nakagawa A, Hamada H, Fujita S, Hattori H, Ohama T, Nishida M, Hiraoka H, Matsuzawa Y, Yamashita S	Accelerated Atherogenicity in Tangier Disease	J Atheroscler Thromb.	25	1076-1085	2018
Nohara A, Ohmura H, Okazaki H, Ogura M, Kazuo Kitagawa, Koseki M, Sato K, Tsukamoto K, Yamashita S	Statement for Appropriate Clinical Use of PCSK9 Inhibitors	J Atheroscler Thromb.	25	747-750	2018
Liu J, Nishida M, Inui H, Chang J, Zhu Y, Kanino K, Matsuda H, Sairyo M, Okada T, Nakaoka H, Ohama T, Masuda D, Koseki M, Yamashita S, Sakata Y.	Rivaroxaban Suppresses the Progression of Ischemic Cardiomyopathy in a Murine Model of Diet-Induced Myocardial Infarction.	J Atheroscler Thromb.		March 14th	2019
Kurano M, Ikeda H, Iso-O N, Hara M, Tsukamoto K, Yatomi Y.	Regulation of the metabolism of apolipoprotein M and sphingosine 1-phosphate by hepatic PPAR activity.	Biochem J.	475(12)	2009-2024	2018

Nohara A. Ohmura H. Okazaki H. Ogura M. Kitagawa K. Koseki M. Sato K. Tsukamoto K. Yamashita S.	Statement for Appropriate Clinical Use of PCSK9 Inhibitors.	Journal of Atherosclerosis and Thrombosis	25(8)	747-750	2018
Sakamoto M. Edono N. Takahashi S. Okamura E. Uno K. Morita K. Ishikawa T. Asahi K. Iseki K. Moriyama T. Yamagata K. Tsuruya K. Fujiimoto S. Narita I. Konta T. Kondo M. Kimura K. Ohashi Y. Watanabe T. Tsukamoto K	Association between prescription and control status of dyslipidemia and hypertension among Japanese diabetic patients.	Journal of Atherosclerosis and Thrombosis	in press	in press	in press
Kurano M. Hasegawa K. Kunimi M. Hara M. Yatomiyama Y. Teramoto T. Tsukamoto K.	Sitosterol prevents obesity-related chronic inflammation.	BBA - Molecular and Cellular Biology of Lipids	1863(2)	191-198	2018
小山信吾, 関島良樹	脳腱黄色腫症の過去・現在・未来	The Lipid	30	52-57	2019
黒田正幸、横手幸太郎	家族性LCAT欠損症の過去・現在・未来	The Lipid	Vol.30 No.1	71-78	2019
三井田孝	LDLコレステロール(直接法)とnon-HDLコレステロール.	臨床病理	66(10)	1102-1109	2018
三井田孝	LDL-C 値の測定法 には計算式と直接法がありますが、使い分けや注意点はありますか？	検査と技術	46(7)	794-798	2018
三井田孝	LDLコレステロール直接法の実際.	日医雑誌	147(5)	980	2018
中川 嘉, 島野仁	【脂質異常症の最前線】脂質代謝におけるPPAR とFGF21の役割	Medical Science Digest	44 巻 14 号	768-771	(2018.12)
塚本和久	薬物の併用療法・副作用・アドヒアランス 動脈硬化性疾患予防ガイドライン2017	The Lipid	29(1)	76-81	2018
塚本和久	薬物療法 動脈硬化性疾患のリスク評価と管理	日本冠疾患学会雑誌	24(1)	32-37	2018

塚本和久	糖尿病を含めた高リスク病態における脂質管理	板橋区医師会 通報	494	84-87	2018
塚本和久	治療抵抗性高コレステロール血症のくすり	スズケンファーマ	21(1)	7	2018
塚本和久	治療抵抗性高コレステロール血症とは	スズケンメディカル	21(1)	15	2018
塚本和久	動脈硬化性疾患予防ガイドライン2017年版のポイント	プラクティス	35(3)	250-256	2018
塚本和久	動脈硬化危険因子の評価	日本医師会雑誌	147(5)	965-969	2018
塚本和久	脂質異常症治療の最近の話題	帝京大学医師会報告	38	4	2018
塚本和久	マイクロソームトリグリセリド転送蛋白(MTP):機能そして治療標的として	Pharma Medica	36(10)	35-38	2018
塚本和久	MTPの生理的役割と脂質異常症 脂質異常症の最前線	Medical Science Digest	44(14)	32-35	2018
土橋一重	動脈硬化予防のための脂質異常症治療最前線 小児の脂質異常症治療	日本医師会雑誌	147	1008-1012	2018
土橋一重	生涯教育問題 「脂質異常症」に関する問題 小児(15歳未満)の動脈硬化予防について正しいのはどれか。1つ選べ。	日本医師会雑誌	147	1015	2018
土橋一重	私の処方2018 内分泌・代謝疾患の処方 家族性高コレステロール血症	小児科臨床	71	947-952	2018
土橋一重	動脈硬化性疾患予防ガイドライン2017 12.小児	The Lipid	29	98-102	2018
土橋一重	スタチンを誰にどのように使うのか? 1.小児の家族性高コレステロール血症患者にスタチン処方を考慮すべきですか?	Modern Physician	39	159-161	2019
土橋一重	【小児疾患の診断治療基準】脂質異常症	小児内科	50	190-191	2018
男澤悠貴、塚本和久	各脂質異常症の病態と治療 低HDLコレステロール血症	臨床と研究	96(1)	33-37	2019
高橋学,石橋俊	【原発性高脂血症研究の過去・現在・未来】無リポ蛋白血症の過去・現在・未来	The Lipid	30巻1号	87-93	2019年

岡崎啓明	高トリグリセリド血症 動脈硬化ハイリスク遺伝子と新たな制御手段への期待	東京都医師会雑誌	71(4)	293-298	2018
岡崎啓明	高中性脂肪血症 成因、診断、治療	Medical Practice	36(1)	55-63	2019
岡崎啓明	原発性高カイロミクロン血症の過去・現在・未来	The Lipid	30(1)	58-70	2019
岡崎啓明	高中性脂肪血症の遺伝子-環境関連 apoA-V欠損症からの新知見	医学のあゆみ	268(5)	403-408	2019
小関正博	コレステロールの基礎と臨床的意義	日本栄養士会雑誌		14-17	2018
小関正博	脂質異常症のHot Topics-動脈硬化性疾患ガイドライン2017の改訂をふまえて-	西宮市医師会医学雑誌		167-173	2018
小関正博	心血管・動脈硬化性疾患～肝臓が心血管を征服する～	臨床雑誌「内科」		1315-1317	2018
小関正博	オキシステロールと動脈硬化	Heart View		65-70	2018
小関正博	LDL-C, HDL-C, TG, Non-HDL-C, TC	臨床精神医学		427-437	2018
小関正博	小腸におけるコレステロール吸収と動脈硬化	Pharma Medical		57-60	2018
村津淳、小関正博、山下静也	タンジール病の過去・現在・未来	The Lipid		79-86	2019
小関正博	重症家族性高コレステロール血症に対する根治的療法の開発 - 同種脂肪組織由来多系統前駆細胞移植療法 -	Medical Practice		105-108	2019
小関正博	NAFLD/NASHと動脈硬化をつなぐ分子メカニズム	医学のあゆみ 動脈硬化 update		369-373	2019
小関正博	NAFLD/NASHを合併した心血管疾患	Heart View		30-35	2019
小倉正恒	私の処方：家族性高コレステロール血症ヘテロ接合体	Modern Physician	38(11)	1183	2018
小倉正恒、斯波真理子	PCSK9阻害薬を用いた脂質低下治療の展望と課題	最新医学	73(6)	837-842	2018
小倉正恒、斯波真理子	疾患レビュー・治療抵抗性高コレステロール血症	スズケンメディカル	21(1)	4-6	2018

小倉正恒、斯波真理子	疾患SUMMARY・治療抵抗性高コレステロール血症	スズケンファーマ	21(1)	6	2018
小倉正恒、斯波真理子	家族性高コレステロール血症のリスク評価と管理	日本冠疾患学会雑誌	24(1)	42-45	2018
小倉正恒	家族性高コレステロール血症の診断と治療に新ガイドラインを生かす	Mebio	35(3)	76-83	2018
小倉正恒、斯波真理子	家族性高コレステロール血症の診断と治療のコツ	CLINIC magazine	590	21-27	2018
小倉正恒、斯波真理子	家族性高コレステロール血症の分子標的	循環器専門医	27	64-71	2018
小倉正恒	<企画・編集>スタチンを使いこなす! 18のクリニカル・パールズ	Modern Physician	39(2)	147-215	2019
小倉正恒	家族性高コレステロール血症ホモ接合体研究の過去・現在・未来	The Lipid	30(1)	38-43	2019
小倉正恒、斯波真理子	抗PCSK9核酸医薬の登場が意味するもの	医学のあゆみ「第1土曜特集 動脈硬化 UPDATE」	268(5)	438-442	2019